Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: A BENEFIT study analysis

Multiple Sclerosis Journal

Volumn 18, Issue 7, 2012, Pages 966-973

  Freedman, Mark S ^a   Metzig, C ^b   Kappos, L ^c   Polman, C H ^d   Edan, G ^e   Hartung, H P ^f   Miller, D H ^g   Montalban, X ^h   Yarden, J ⁱ   Spector, L ⁱ   Fire, E ⁱ   Dotan, N ⁱ   Schwenke, S ^b   Lanius, V ^b   Sandbrink, R ^b,f   Pohl, C ^b,j  

^a UNIVERSITY OF OTTAWA   (Canada)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Clinique Neurologique   (France)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ Glycominds Ltd   (Israel)

^j UNIVERSITY HOSPITAL BONN   (Germany)

more..

Author keywords

antibody; biomarker; clinically definite multiple sclerosis; clinically isolated syndrome; Expanded Disability Status Scale; multiple sclerosis; prognosis

Indexed keywords

ALPHA GLUCOSE ANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN M ANTIBODY; INTERFERON BETA SERINE; PLACEBO; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ANTIBODY TITER; ARTICLE; CLASSIFICATION; COHORT ANALYSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISABILITY; DISEASE ACTIVITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; RELAPSE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THERAPY DELAY;

EID: 84863215864     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511432327     Document Type: Article

References (34)

1. McAlpine D. The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 1961; 84: 186-203.
2. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419-1428. (Pubitemid 20024212)
3. Runmarker B and Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty five years of follow-up. Brain 1993; 116: 117-134. (Pubitemid 23087038)
4. Achiron A and Barak Y. Multiple sclerosis from probable to definite diagnosis: a 7 year prospective study. Arch Neurol 2000; 57: 974-979. (Pubitemid 30452502)
5. Galboiz Y and Miller A. lmmunological indicators of disease activity and prognosis in multiple sclerosis. Curr Opin Neurol 2002; 15: 233-237. (Pubitemid 34596883)
6. O'Riordan JI, Thompson AJ, Kingsley DPE, MacManus DG, Kendall BE, Rudge P et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998; 121: 495-503. (Pubitemid 28116346)
7. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ and Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-164. (Pubitemid 34438881)
8. Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus DG, Plant GT et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002; 52: 47-53. (Pubitemid 34693742)
9. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817. (Pubitemid 351294716)
10. Tintoré M, Rovira A, Río J, Nos C, Grivé E, Téllez N et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968-972. (Pubitemid 44454586)
11. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-145. (Pubitemid 36818783)
12. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356: 371-378. (Pubitemid 46148779)
13. Pelayo R, Tintoré M, Montalban X, Rovira A, Espejo C, Reindl M et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 2007; 356: 426-428. (Pubitemid 46148809)
14. Schwarz M, Spector L, Gortler M, Weisshaus O, Glass-Marmor L, Karni A et al. Serum anti-Glc(alphal,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci 2006; 244: 59-68.
15. Brettschneider J, Jaskowski TD, Tumani H, Abdul S, Husebye D, Seraj H et al. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol 2009; 217: 95-101.
16. Freedman MS, Laks J, Dotan N, Altstock RT, Dukler A and Sindic CJ. Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event. Mult Scler 2009; 15: 422-430.
17. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846. (Pubitemid 41746873)
18. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH et al. BENEFIT Study Group. Long-term effect of early treatment with interferon beta 1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987-997.
19. Schwarz M, Spector L, Gargir A, Shtevi A, Gortler M, Altstock RT et al. A new kind of carbohydrate array, its use for profiling antiglycan antibodies, and the discovery of a novel human cellulose-binding antibody. Glycobiology 2003; 13: 749-754. (Pubitemid 37407104)
20. Masjuan J, Alvarez-Cermeño JC, García-Barragán N, Díaz-Sánchez M, Espiño M, Sádaba MC et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006; 66: 576-578. (Pubitemid 43739891)
21. Tintoré M, Rovira A, Río J, Tur C, Pelayo R, Nos C et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70: 1079-1083. (Pubitemid 351464763)
22. Confavreux C, Vukusic S, Moreau T and Adeleine P. Relapses and progression of disability in multiple sclerosis. New Engl J Med 2000; 343: 1430-1438.
23. Confavreux C, Vukusic S and Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-782. (Pubitemid 36372978)
24. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010; 133: 1914-1929.
25. Lublin FD, Baier M and Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528-1532. (Pubitemid 37505574)
26. Lublin FD. The incomplete nature of multiple sclerosis relapse resolution. J Neurol Sci 2007; 256: S14-S18. (Pubitemid 46560637)
27. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH et al. Treatment with interferon beta 1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249. (Pubitemid 44563835)
28. Degenhardt A. Ramagopalan SV, Scalfari A and Ebers GC. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol 2009; 5: 672-682.
29. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582. (Pubitemid 32488815)
30. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
31. Comi G, Martinelli V, Rodegher M, Durelli L, Edan G, Fernández O et al; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511.
32. Freedman MS. Induction vs. escalation of therapy for relapsing multiple sclerosis: the evidence. Neurol Sci 2008; 29: S47-S51.
33. Miller JR. The importance of early diagnosis of multiple sclerosis. J Manag Care Pharm 2004; 10: S4-S11.
34. Kantarci OH. Weinshenker BG. Prognostic factors in multiple sclerosis. In Cook SD, (ed.) Handbook of Multiple Sclerosis, third edition. New York: Marcel Dekker, 2001, pp. 449-463.